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Mesenchymal stem cells (MSCs) are pluripotent cells isolated from the bone marrow and various other organs. They are able
to proliferate and self-renew, as well as to give rise to progeny of at least the osteogenic, chondrogenic, and adipogenic lineages.
Despite this functional deﬁnition, MSCs can also be deﬁned by their expression of a distinct set of cell surface markers. In the
current paper, studies investigating the proteome of human MSCs are reviewed with the aim to identify common protein markers
of MSCs. The proteomic analysis of MSCs revealed a distinct set of proteins representing the basic molecular inventory, including
proteins for (i) cell surface markers, (ii) the responsiveness to growth factors, (iii) the reuse of developmental signaling cascades in
adult stem cells, (iv) the interaction with molecules of the extracellular matrix, (v) the expression of genes regulating transcription
and translation, (vi) the control of the cell number, and (vii) the protection against cellular stress.
1. Why Do We Study MSC Proteomes?
The human bone marrow consists of a heterogenous
group of cells, including hematopoietic stem cells (HSCs),
endothelialcells,ﬁbroblasts,adipocytes,andosteogeniccells.
Additionally, in recent years, another group of cells has been
found which are able to proliferate and self-renew, as well as
diﬀerentiate into cells of the mesenchym such as osteoblasts,
chondrocytes, and adipocytes (Figure 1). These cells were
called mesenchymal stem cells (MSCs), but there is a signif-
icant controversy about a consensus deﬁnition of MSCs—
which at least can be seen in the large number of names for
these cells, all used simultaneously, for example, mesenchy-
mal stem cells, mesenchymal stromal cells, marrow stromal
cells, mesodermal progenitor cells, marrow-isolated adult
multilineage inducible (MIAMI) cells, or CFU-F (colony-
forming unit ﬁbroblastic) (reviewed and discussed in [1]).
The interest in MSCs has risen since there is hope to use
these cells in regenerative medicine, for example, in acute
myocardial infarction and cardiovascular disease, diabetes,
stroke, kidney disease, or immunomodulatory disease such
as graft-versus-host disease (GvHD) [2–4]. Therefore, it is
necessary to know the set of proteins which is responsible for
thecellularfunctions.Inrecentyears,proteomics emergedas
a large-scale screening tool for both creating a protein inven-
tory and to identify protein functionality. Major techniques
of proteomics include two-dimensional gel electrophoresis
for the separation of proteins and various mass spectrometry
techniques for sequence identiﬁcation [5].
In this paper, I will concentrate on the proteomic ana-
lysis of human MSCs, explicitly excluding MSCs isolated
from other species (with several exceptions), or other stem
cells diﬀerentiated into mesenchymal tissues in a strict
sense, which are bone, cartilage, and fat, as well as MSCs
diﬀerentiatedintononmesenchymaltissuessuchasneuralor
glial cells.
2. The Dilemma of a Consensus Deﬁnition
o fM e s e nc h ym alS t e mC ell s :H et e r og e no us
Origins andProperties
A functional deﬁnition of MSCs seems to be a straight-
forward approach, with MSCs fulﬁlling the following two
criteria: (i) MSCs can be propagated in cell culture, where
they adhere to the plastic well surface, and (ii) they can
be stimulated to diﬀerentiate into osteoblasts, chondrocytes,
and adipocytes. This deﬁnition is similar to the functional
deﬁnition of other stem cell types, for example, for neural
stem cells [6]. Of note, this deﬁnition excludes the trans-
diﬀerentiation potential of MSCs into stem cells of other
lineages, such as hematopoietic stem cells (HSCs), neural
stem cells (NSCs), or epithelial stem cells. The concept of2 Stem Cells International
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Figure 1: Scientiﬁc publications in PubMed about MSCs. The
PubMed database was searched for the terms “mesenchymal stem
cell,” “mesenchymal stromal cell,” and “MSC” for the years 1990–
2009. The emerging interest in MSCs is seen by the increasing
number of publications.
stem cell transdiﬀerentiation is still under discussion and
m a yb ea na r t i ﬁ c i a lo n e[ 1, 7–10].
Besides the bone marrow, cells with regenerative poten-
tial have been isolated from the skeletal muscle [15], adipose
tissue [16], umbilical cord [17], dental pulp [18], synovia
[19], the circulatory system [20] ,a n da m n i o t i cﬂ u i d[ 21]a s
wellasfetalblood,liver,bonemarrow,andlung[22–24].The
list (exceeding more than 30 organs by now) only shows that
the tissue of origin cannot be used for the characterization
of MSCs. Thus, we will concentrate in this paper on cells
isolated from the bone marrow (BM-MSCs).
3. Cytochemicaland Immunochemical
Characterization
The cellular morphology played a major part in identifying
MSCs in vitro. In general, immature MSCs appear as small,
spindle-shaped cells, whereas mature MSCs display as larger
cells with a ﬂat, polygonal morphology. With regard to
cellular staining techniques, MSCs were stained positive
with sudan black, alkaline phosphatase, collagen IV, and
ﬁbronectin, whereas they are negative to esterase staining
[25, 26].
With regard to immunocytochemical methods, the
murine IgM monoclonal antibody STRO-1 identiﬁed bone
marrow stromal cells distinct from HSCs [27]. Soon, several
other surface proteins were identiﬁed which are speciﬁc
for BM-MSCs [28]. In recent years, a panel of cell surface
antigens emerged to characterize MSCs (compiled in [4];
see also Figure 2). According to these panels, negative and
positive selection markers of MSCs have been deﬁned. MSCs
do not express CD34, CD45, CD117 (cKit), HLA class I,
and HLA-DR antigens, whereas they are positive for CD13,
CD29, CD44, CD73, CD90, CD105, and CD166. These
markers are located in the cell membrane of the MSCs, and
antibodiesarereadilyavailableforFACSanalysisandsorting.
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Figure 2: Expression of cell surface markers of MSCs. Hierarchical
clustering of the expression of cell surface markers of MSCs from
diﬀerentMSCspreparations.Cellsweretermed“mesenchymalstem
cells (MSCs)” [11], “mesodermal progenitor cells (MPCs)” [12],
“marrow-isolatedadultmultilineageinducible(MIAMI)cells”[13],
and “bone marrow-isolated mesenchymal stem cells (BM-MSCs),”
“adipose tissue-isolated stem cells (ADSCs),” “synovia-derived stem
cells (SynoSCs),” “umbilical vein stem cells (UVSCs),” and “human
embryonic stem cells (hESCs)” [14]. The ﬁgure shows the diﬀerent
cell preparations in columns and the surface antigens in rows. The
green color codes for positive expression, yellow codes for low
expression, red codes for no expression, and grey color stands for
notdeterminedintherespectiveexperiments.Itisseenthatthecells
can be deﬁned by the presence and absence of a distinct pattern of
cell surface markers, that is, CD34(−), CD45(−), CD117(−)( c K i t ) ,
CD44(+), CD90(+), and CD166(+).
4. Proteomics of Bone Marrow-DerivedMSCs
4.1. Proteome Inventories. In a recent review, the basic
protein inventory of a “typical” MSC has been compiled
[29], including speciﬁc proteins of the cellular metabolism,
ion transport, and their respective receptors, or channels,
cytokines, chemokines, growth factors, and their respec-
tive receptors, proteins of stroma-dependent hematopoiesis,
extracellular matrix and connective tissue proteins, calcium
homeostasis, cell cycle regulation and cellular aging, trans-
port proteins, protein for posttranslational protein modi-
ﬁcations, cellular detoxiﬁcation, genomic transcription and
translation pathways, a speciﬁc set of cell surface molecules
(see also Figure 2), diﬀerentiation and development, struc-
tural components and cytoskeleton, and folding of proteins
and stress response proteins (chaperones). Although no
single molecule has been identiﬁed as a speciﬁc marker for
MSCs, and all proteins of the list have also been found in
other cell expression studies, the set of proteins and their
expression arrangement is speciﬁc for MSCs.
Comparing two diﬀerent approaches for MSC culture
conditions, Wagner et al. [30] isolated MSCs from the boneStem Cells International 3
marrow of healthy human donors and performed 2DE and
subsequent MS to identify a set of 136 proteins. The authors
compared the proteomic data to gene chip proﬁling data
for an integrated approach and found, after interchanging
media between the two groups after 8 days, that culture
conditions reversed the gene and protein expression proﬁles.
In conclusion, it is important to control and report culture
conditions in details, since these experimental conditions
highly inﬂuence gene and protein expression. This makes it
diﬃcult to compare experiments with diﬀerent cell culture
conditions [31].
A recent study compared the cellular proteomes of
MSCsisolatedfrombonemarrow(BM-MSC),adiposetissue
(ADSC), synovial membrane (SynoSC), and umbilical vein
wall (UVSC) [14], ﬁnding a close correlation of protein
expression patterns between BM-MSCs and ADSCs. The
authors used cells with the immunophenotype CD90(+),
CD73(+), CD105(+), CD44(+), CD45(+) for BM-MSC,
ADSC, SynoSC, and UVSC. Additionally, ADSC expressed
CD34, and UVSC did not express CD106. The authors used
2DE to separate about 850 protein spots, of which 232 could
be identiﬁed by MS.
The proteomic comparison of rat BM-MSCs from young
and old animals [32] revealed the diﬀerential expression
of Beta-actin FE-3, Caldesmon l, Calponin-l, E-FABP
(C-FABP), Galectin 3, Gamma synuclein, Heterogeneous
nuclear ribonucleoprotein Al isoform a and A2/Bl isoform
A2, Huntingtin interacting protein K, Myosin light chain,
Peroxiredoxin 5, Pyruvate dehydrogenase (lipoamide) beta,
and Transgelin. These proteins can be divided into the
functional groups of cytoskeletal rearrangement, cellular
ageing, and metabolism. Moreover, these proteins were also
expressed under osteogenic diﬀerentiation.
A problem of MSC cultures is that the cells cannot
be propagated over a longer period of time because of
intrinsic diﬀerentiation programs. Within a few passages, the
MSCs lose their proliferation potential. In a proteomic study
using 2DE and LC-MS/MS, Lee at al. [33] found that the
addition of 10ng/mL basic ﬁbroblast growth factor (bFGF)
diﬀerentially regulated the expression of 15 proteins, of
which actin-related protein 2/3 complex subunit 2 (ARPC2),
isoform 2 of glial ﬁbrillary acidic protein (GFAP), lamin-
A/C (LMNA), ubiquinol-cytochrome c reductase complex
core protein 1 (UQCRC1), the multifunctional protein
ADE2 (PAICS), F-actin-capping protein subunits alpha-1
(CAPZA1) and alpha-2 (CAPZA1), Septin-2 (SEPT2), and
elongation factor 1-gamma (EEF1G) have been upregulated
and Myosin regulatory light chain (MRLC2), desmoplakin
(DSP), proteasome subunit alpha type 5 (PSMA5), and heat
shock protein beta-1 (HSPB1) have been downregulated
more than 2-fold. The functional classiﬁcation of these
proteins showed that these proteins mainly belonged to
structural and cell morphology regulating groups, indicating
that bFGF might regulate MSC diﬀerentiation and structure.
4.2. Myogenic Diﬀerentiation. Wang et al. used commercially
available MSCs which are positive for CD105, CD166, CD29,
and CD44, and negative for CD34, CD14, and CD45 in
MSCGMmediacomplementedwithfetalbovineserum[34].
They cultured the MSCs up to ten passages before 2DE.
Formyogenic diﬀerentiation, theauthorsstimulated thecells
for four days with 10ng/mL TGF-β and identiﬁed about 30
proteins with diﬀerential expression, among them smooth
muscle actin-alpha and gelsolin.
To induce myogenic diﬀerentiation in human MSCs,
Kurpinski et al. [35] used 5ng/mL TGF-β1 and uniaxial
mechanical stress. After 24h, the authors subjected the cells
to 2DE and Q-TOF (quadrupole time of ﬂight) MS. They
identiﬁed 12 proteins which were upregulated, including
eukaryotic translation elongation factor 2 (EF2), trans-
forming growth factor-beta-induced protein ig-h3 (BGH3),
calponin 3 (CNN3), tropomyosin, actin-related protein 3
(ARP3), and smooth muscle actin-gamma. All of these
proteins may be involved in myogenesis.
In a proteomic study investigating the secretome of
murine BM-MSCs by LC-MS/MS, Sarojini et al. [36] identi-
ﬁed 19 proteins, including ﬁbronectin, pigment epithelium-
derived factor (PEDF), collagen A2(I), myocilin, clusterin,
protein-lysine 6-oxidase, biglycan, cathepsin L, peptidyl-
prolyl cis-transisomerase, nucleobindin, procollagen c-
proteinaseenhancerprotein,collagenA1(I)chain,Dickkopf-
related protein-3 (Dkk-3), ﬁbulin-2, β-2-microglobulin,
CTLA-2-alpha protein, cystatin c, galectin-3, and moesin. In
a cell migration assay, the secretome was applied to human
ﬁbroblast cultures. In this assay, the chemotactic migration
towards to PEDF-containing secretome was increased, sug-
gesting a function in tissue rearrangement.
4.3. Adipogenic Diﬀerentiation. The adipogenic diﬀerentia-
tion of commercially available human MSCs was investi-
gated by the addition of 10% FBS, 1μM dexamethasone,
0.5mM methyl-isobutylxanthine, 10μg/mL h-insulin, and
10mM indomethacin to the cell culture media for 14
days [37]. The MSCs expressed CD90, but not CD34 and
CD45. After 2DE and MALDI-TOF/MS, the authors iden-
tiﬁed syntaxin binding protein, oxysterol binding protein-
3- (OSBP-) related protein, phosphodiesterase PDE9A12,
glycophorin, immunoglobulin kappa chain variable region,
PPAR-gamma, and T-cell receptor V-beta 4 as new or
overexpressed protein spots.
In commercially available BM-MSCs, which are
CD14(−), CD29(+), CD34(−), CD44(+), CD45(−),
CD105(+), and CD166(+), Ju et al. investigated the whole
cell proteome and membrane proteome by 2D-DIGE and
LC-MS/MS during adipogenic diﬀerentiation [38]. Cells
were incubated for 3 weeks in the LG-DMEM diﬀerentiation
media containing 0.5mM 3-isobutyl-1-methylxantine,
1mM hydrocortisone, 0.1mM indomethacin, and 10% FBS.
The authors identiﬁed more than 700 proteins, including
33CD marker proteins, most of which are already known
for MSCs, a large number of solute carriers, and several
integrins, which are specialized cell surface molecules for
cell-cell interaction and adhesion to the extracellular matrix.
Moreover, more than 30 proteins were only identiﬁed in
the diﬀerentiated MSCs, most of which were metabolic
enzymes.4 Stem Cells International
4.4. Osteogenic Diﬀerentiation. In a one-dimensional pro-
teomic study based on polyacrylamide gel electrophoresis
(SDS-PAGE) protein separation and LC-MS/MS, Chiellini
et al. [39] searched “secretome”, that is, the cell culture
supernatant, for secreted proteins of human multipotent
adipose tissue-derived stem (hMADS) cells during adipoge-
nesis and osteogenesis. The authors listed 73 proteins in the
secretome,ofwhichtheplasminogenactivatorinhibitorPAI-
1 was found only in the osteogenic diﬀerentiation group,
implicating a possible regulator between adipogenesis and
osteogenesis.
Interestingly, the transplantation of MSCs into the tran-
sgenic PAI-1−/− mouse increased graft survival [40]. The
authors also analyzed the MSC cell culture supernatant after
hypoxia by LC-MS/MS, ﬁnding 11 upregulated proteins,
including brevican, IGF binding proteins 2, 4, and 5,
myeloperoxidase, ceruloplasmin, biglycan, serine proteinase
inhibitor El (PAI-1), vascular endothelial growth factor A,
apelin, and superoxide dismutase 3, and 9 downregulated
proteins, including IGF-2 binding protein 3, serine hydrox-
ymethyl transferase 1, hepatoma-derived growth factor,
chemokine (CC motif) ligand 2, desmoplakin, apolipopro-
tein D, Kit oncogene, secreted frizzled-related sequence
protein 1, and interferon zeta.
Sun et al. [41] subcultured BM-MSCs for 14 days in
osteogenic media containing 10mM β-glycerophosphate,
100nM dexamethasone, and 50mg/mL ascorbic acid-2-
phosphate. They compared protein extracts by 2DE and MS
to undiﬀerentiated BM-MSCs, mapping more than 1,000
proteins on the gels. They found the upregulation of 8
proteins, including Annexin A1 and A2, Pyruvate kinase 3
(muscle), Enolase 1, Heat shock 27kD protein 1, Protein
disulﬁde isomerase-related protein, Proteasome 26S ATPase
subunit 5, and Cathepsin D, as well as the downregulation of
4 proteins, including T-complex protein 1, Proteasome 26S
ATPase subunit 2, Cadherin-2, and Chaperonin containing
TCP1, subunit 3. Moreover, the authors compared serial
subcultures to construct a time-resolved expression pattern
for the MSC subcultures.
Using an immortalized human telomerase reverse tran-
scriptase transduced MSC line (MSC-TERT), Foster et
al. enriched protein extracts for membrane proteins and
searched for diﬀerentially expressed proteins after osteoblas-
tic diﬀerentiation by liquid chromatography (LC) and MS
[42]. The authors identiﬁed 463 proteins, including MSCs
phenotype CD71, CD105, CD166, CD44, Thy1, CD29, and
CD63. Upon diﬀerentiation, the expression of 83 proteins
increased, including alkaline phosphatase (ALP), versican
core protein, and tenascin, and 21 proteins decreased more
than 2-fold, including fatty acid synthase.
Kratchmarova et al. [43] investigated the eﬀects of
50ng/mL EGF, or 10ng/mL PDGF for 3 days on the
osteogenic diﬀerentiation of hMSC-TERT cells by LC-
MS/MS.WhereasEGFstimulatedboneformation,PDGFdid
not. Proteins which were found only in the EGF-treated cells
included EGFR, ErbB2, c-Cbl, DOC-2, Acid phosphatase
1, Ribonuclease inhibitor, CYLD, and KIAA2002, whereas
proteins only found in the PDGF-treated group included
PDGFR alpha and beta, PI-3K (p85-alpha, p85-beta, p110-
alpha, p110-beta, p110-delta), Fyn, and Protocadherin 43.
4.5. MSCs and Cancer Proteomics. Whereas the self-renewal
and multipotency of stem cells largely contribute to the
hope of cell and tissue regeneration strategies in disease,
recent data nourished the hypothesis that stem cells may
alsocontributetotumorgeneration.Theircancer-generating
potential is not only seen in embryonic stem cells (ESCs),
but also in MSCs, or in cells with similar potential,
termed cancer-associated ﬁbroblasts (CAFs) and circulating
endothelial progenitors (CEPs) [44–46]. Therefore, the pro-
tein analysis of tumor-generating stem cells may contribute
to the mechanisms of tumorigenesis.
With regard to the proteomic analysis of leukemic
stromalcells,BM-MSCsfromhealthydonorswerecompared
to leukemic cells using liquid phase IEF, 2D-DIGE, MALDI-
MS/MS, and iTRAQ methods [48, 49]. The author found
more than 900 proteins in the MSC samples by liquid phase
IEF and resolved more than 5,000 protein spots on the
2D gels. In total, 34 proteins showed increased expression
in leukemic stromal cells compared to nonleukemic MSCs,
whereas 39 proteins showed decreased expression. Most of
the diﬀerentially expressed proteins belonged to proteins
with functions in transcription and metabolic regulation.
5. Proteomics of Umbilical Cord-Derived
MSCs (UCB-MSCs)
MSCs can also be isolated from the umbilical cord blood by
the same means as BM-MSCs [50]. Whereas the functional
criteria remain comparable (adhesion to the plastic surface),
cell surface markers diﬀer largely and can be used to
distinguish between BM-MSCs and UCB-MSCs.
One of the ﬁrst studies creating a proteomic inventory
of umbilical cord-derived mesenchymal stem cells (UCB-
MSCs) was from our own group [47]. We used CD29(+),
CD44(+), CD73(+), CD90(+), HLA-class I(+), CD14(−),
CD34(−), CD133(−), and HLA-class II(−). We separated
more than 2045 protein spots by 2DE and identiﬁed 205
proteins by MS. The identiﬁed proteins could be grouped
into functional categories, such as metabolism, folding,
cytoskeleton, transcription, signal transduction, protein
degradation, detoxiﬁcation, vesicle/protein transport, cell
cycle regulation, apoptosis, and calcium homeostasis. In the
direct comparison, the proteomes of this UCB-MSC prepa-
ration and of BM-MSCs are largely congruent, but there
are still distinct diﬀerences in the protein expression pattern
(Figure 3). Thus, the concept of the protein deﬁnition of
MSCs evolved accordingly to the NSC proteomic deﬁnition
[6, 51].
A major problem of 2DE is that hydrophobic proteins of
the cell surface cannot easily be isolated in the same sample
preparation as the hydrophilic proteins [5]. With regard to
MSCs, Jeong et al. described the proteome preparation of
hydrophobic proteins from UCB-MSCs [52]. The authors
identiﬁed 35 proteins, providing additional insight into the
cell surface composition of UCB-MSCs.Stem Cells International 5
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Figure 3: Comparison of 2DE gels of BM-MSCs and UCB-MSCs. This ﬁgure shows representative 2D gel images of (a) bone marrow
(BM-)MSC proteins and (b) umbilical cord blood (UCB-)MSC proteins. (c) The false-colored overlay image of the two 2D gels shows the
BM-MSC proteins colored in red, and the UCB-MSC proteins colored in green. The resulting overlaid color is yellow (data from [30, 47]).
The overlaid gel images show a close relationship between the two cellular proteomes, but there seem to be more proteins in the BM-MSC
g r o u pa sw e l la ss o m ed i ﬀerences in protein expression, as seen in the unique color in one of the gels.
A recent study compared the proteomes of UCB-MSCs,
BM-MSCs, and placenta-derived MSCs by 2DE and MS
[53] .T h ei m m u n o p h e n o t y p eo fa l lc e l lp r e p a r a t i o n sw a s
CD29(+), CD44(+), CD90(+), CD105(+), CD166(+),
CD45(−), HLA-DR(−), CD3(−), CD16(−), CD19(−),
CD33(−), CD38(−), CD34(−), and CD133(−). All cell
preparations could be diﬀerentiated into bone and fat
cells. The authors identiﬁed six diﬀerentially regulated
proteins, that is, superoxide dismutase [Mn] (MnSOD), heat
shock protein HSPA9, cathepsins B and D, prohibitin, and
plasminogen activator inhibitor PAI-1.
Roche et al. did not use MSCs from the umbilical cord
blood, but from the umbilical cord vein walls [14]. The
authors compared the proteomes to other MSC preparations
(see discussion above).
6. The Concept of Dedifferentiation Is
Still a Matter of Debate
There is one proteomic study based on 2DE and MS inves-
tigating the dediﬀerentiation potential of murine ﬁbrob-
lasts, which showed similar expression patterns with regard
to cytoskeletal and cell shape remodeling, RNA export,
degradation, folding, stress control, and ATP production
[54]. Although dediﬀerentiation was initiated using the
synthetic purine “reversine” (2-(4-morpholinoanilino)-6-
cyclohexylaminopurine), the general concept of dediﬀeren-
tiation is still under discussion [55–57], also in the respective
proteomic study, since no rediﬀerentiation experiments
showing the proposed multipotentiality of the dediﬀerenti-
ated cells have been shown.
7. Molecular Deﬁnitions of MSCs
Using 2DE Experiments
With regard to proteomic analyses, proteomic inventories
of MSCs have been created using two-dimensional gel
electrophoresis. Additionally, the events underlying cellular
diﬀerentiation in vitro have been studied in osteogenesis,
adipogenesis, and chondrogenesis.
Comparing the protein expression patterns, no single
characteristic molecule could be identiﬁed, but the func-
tional deﬁnition, as speciﬁed for the genomic approaches,
is supported. In the light of these results, adult stem cells
have all the same prerequisites, but the exact molecular
composition is dependent on cell and tissue-speciﬁc factors
[51, 58]. These common prerequisites involve (Figure 4).
(i) The expression of a speciﬁc set of cell surface markers,
such as CD13, CD29, CD44, CD73, CD90, CD105, and
CD166, and the absence of hematopoietic stem cell markers,
such as CD34, CD45, CD117 (cKit), HLA class I, and HLA-
DR antigens.
(ii) The responsiveness to growth factors and cytokines
such as PDGF, TGF-β, FGF [59], EGF, SDF-1alpha, G-CSF,
GM-CSF, Angiopoietin-1, Angiopoietin-2, BMP-4, BMP-7,
and IFN-gamma (reviewed in [60–62]). Of note, not all
mesenchymal stem cells react to each of these molecules. A
prerequisite to growth factorresponsiveness is the expression
of speciﬁc membrane-spanning receptors, which are able to
initiate intracellular signaling cascades.
(iii) The reuse of developmental signaling cascades in
adult progenitors. Nearly, 20 such pathways have been iden-
tiﬁed in adult stem cells, including Shh, Wnt, Notch/Delta,6 Stem Cells International
Reactiveness to growth factors: e.g, PDGF, TGF-β,
FGF2, EGF, SDF-1α, G(M)-CSF, BMPs and Ang1/2 Cell surface markers,
e.g, CD antigens
Receptor Reactivation of developmental programs:
e.g, Shh, Wnt, Notch/delta, BMP and TGF-β
Stress resistance: e.g,
metabolic enzymes, NO,
cytoskeleton and chaperons
Mitochondria
Regulation of cell number:
e.g, cyclins and caspases
Transcriptional/translational control:
e.g, transcription factors
Transcription
Nucleus
Interaction with the extracellular matrix:
e.g, integrins and cadherins
Extracellular matrix
Figure 4: Proteomic deﬁnition of MSCs—proposal for the protein inventory. The main aspects for a proteomic deﬁnition of MSCs include
(i) the expression of a speciﬁc cell surface markers, (ii) the reactiveness to growth factors, (iii) the re-activation of developmental pathways,
(iv) the interaction with the extracellular matrix, (v) the regulation of transcription and translation, (vi) the regulation of cell number, and
(vii) the machinery for resistance to cellular stress (modiﬁed from [6, 51]).
BMP, and TGF-β (reviewed in [60, 61, 63]). Interestingly, the
activation of these pathways in the adult may have diﬀerent
functions compared to the embryonic developmental path-
ways.
(iv) The interaction with molecules of the extracel-
lular matrix (reviewed in [64, 65]). During diﬀerentia-
tion and maturation, stem cells migrate, extend processes,
attach to the extracellular matrix, and adhere to nearby
microenvironmental surfaces. Therefore, they require the
expression of motor proteins, lytic enzymes, and enzymes
for providing metabolic energy. Several extracellular matrix
proteins mediating cell-cell interaction have been identiﬁed
in mesenchymal stem cells, such as integrins and cadherins.
(v) The expression of genes regulating transcription
and translation (reviewed in [66–69]). Although no speciﬁc
proteins in the categories of transcription factors, DNA or
RNA binding proteins, and chromatin remodeling enzymes
can be named, mesenchymal stem cells need these molecules
to change the cellular phenotype from its undiﬀerentiated
form to the new functional requirements of a diﬀerentiated
mature cell.
(vi) Mechanisms for controlling cell number. Mainly
three processes regulate stem numbers: Mitosis (prolif-
eration), diﬀerentiation, and apoptosis (programmed cell
death). An essential process is also asymmetric cell division,
which regulates the stem cell pool. In this context, typical
proteins regulating cell number are caspases and cyclins.
(vii) The protection against cellular stress (reviewed in
[70]), which involves metabolic deprivation, NO and O2
toxicity, DNA damage, mechanical distortion, hypo- and
hyperthermia, or hypoxia. Proteins in this category have
been identiﬁed in the groups of molecular chaperones, NO-
detoxifying enzymes, and components of the proteasome.
Of note, although mesenchymal stem cells express these
molecules, diﬀerent proteins can be found in diﬀerent
cellularphenotypes.Thisheterogeneityintheproteinexpres-
sion pattern is supported by protein expression studies
comparing mesenchymal stem cells isolated from diﬀerent
organs [14].
8. Conclusions
Human MSCs represent a heterogenous group of stem cells
with a unique potential to diﬀerentiate into mesenchymal
tissue. In this paper, proteomic experiments investigating
human MSCs have been reviewed with the purpose to
ﬁnd common protein expression patterns. Six functional
groups of proteins have been identiﬁed which build the
prerequisite of an MSC proteomics inventory, including
proteins for growth factor responsiveness, reuse of develop-
mentalpathways,regulationoftranscriptionandtranslation,
mechanismscontrollingcellnumbers,andprotectionagainst
cellular stress. The composition of this set is unique, but not
exclusive, for human MSCs.Stem Cells International 7
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